Method of inhibiting trem-1
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsPatrick R. Griffin, Mi Ra Chang, Jason Fisherman, Peter Suzman
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and uses of the polypharmacological modulator SR1903 and related compounds for inhibiting triggering receptor expressed on myeloid cells-1 (TREM-1) and treating diseases and conditions that are related to or mediated by TREM-1, such as inflammatory diseases, autoimmune diseases, metabolic disorders, and castration resistant prostate cancer (CRPC).
Claims28
A method of inhibiting Triggering Receptor Expressed on Myeloid cells 1 (TREM-1) in a subject in need thereof comprising administering to said subject an effective amount of a compound having the formula (I):
- wherein:
- R1 is C1-C4 alkyl substituted with OR or C1-C4 fluoroalkyl substituted with OR;
- R2, R4, and R5 are each independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, and C1-C4 alkoxy;
- R3 is C1-C4 alkyl;
- and
- R is hydrogen or C1-C4 alkyl;
- or a pharmaceutically acceptable salt thereof.
(canceled)
11-13. (canceled)
The method of claim 12, wherein there is a reduction or delay in obesity related thymic involution.
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating a subject suffering from a disease or condition that is related to triggering receptor expressed on myeloid cells-1 (TREM-1), comprising administering to the patient a therapeutically effective amount of the compound SR1903:
- or a pharmaceutically acceptable salt thereof.
28-38. (canceled)
A method of inhibiting TREM-1 in a subject in need thereof comprising administering to said subject an effective amount of a compound that is a RORγ inverse agonist, an inverse agonist of PPARγ, and an agonist of LXR.
40-55. (canceled)
Dependencies are inferred from the claim text.